Kornimate/medical-research-clean huggingface dataset:
automated breast ultrasound case collection registry

Conditions: Breast Cancer

Summary: the contribution of automated breast ultrasound (abus) to the screening pathway for breast cancer is not fully understood. this prospective study aims to collect longitudinal data in women with dense breasts undergoing abus as a supplement to digital breast tomosynthesis (dbt). the data are intended for use in future research on the value and effectiveness of abus in routine clinical care. data will be collected from eligible women who have been prescribed or have completed dbt and abus, screening within a 30-day window. radiologist evaluations and, when performed, outcomes of biopsy and/or laboratory testing will be recorded. subjects will be followed for breast cancer status and results of any diagnostic breast exams and/or treatment.


Eligibility criteria:
inclusion criteria: 1. are asymptomatic adult women (aged 18 years or older); 2. are eligible to complete or have completed (within 30 days) screening abus and dbt exams per the site standard of care;1 3. have heterogeneously dense and extremely dense breasts (bi-rads c or d, respectively) or are determined to have dense breasts prior to the study on initial screening mammography; 4. are able and willing to participate. exclusion criteria: 1. have a breast cancer diagnosis (with or without metastasis) or are being treated for breast cancer within the year prior to the study.
prematurity and ophthalmological changes

Conditions: Retinopathy of Prematurity; Myopia

Summary: ophthalmological differences in school-aged children with and without a history of retinopathy of prematurity

aims: to compare functional (visual acuity and refractive error) and anatomical (biometric values, foveal and choroidal thickness) ophthalmological differences in school-aged children with and without a history of retinopathy of prematurity (rop). settings and design: prospective cross-sectional study methods and material: the study was conducted prospectively in the ophthalmology department of ankara bilkent city hospital. subjects were divided into three groups: 29 children who were treated with laser photocoagulation (rop-txgroup), 26 children who developed rop and did not need treatment (rop-non-txgroup), and 25 children who did not develop rop (premature group). the 27 healthy children with a history of full-term born (control group), who were in a similar age group for 'control eye examination', were accepted as the control group. a total of 107 patients and 211 eyes were included in the study. non-cycloplegic and cycloplegic refraction, best corrected visual acuity (bcva), keratometry, axial length (al) and anterior chamber depth (acd), optical coherence tomography (oct) macular and oct subfoveal choroidal measurements were performed in all cases.

Eligibility criteria:
inclusion criteria: children with a history of rop exclusion criteria: stage 4-5 rop, presence of media opacities (such as cataract) ocular trauma or ocular surgery hydrocephalus or grade 3 and above intracerebral hemorrhage, uncooperative children

Keywords: biometry foveal thickness choroidal thickness laser photocoagulation oct prematurity retinopathy of prematurity
gnrh agonist as luteal support in fet cycles

Conditions: Infertility

Summary: back ground: a single dose of gnrh analogue in the luteal phase is reported to improve the outcome of ivf/icsi treatments but the effect in fet cycles has not been reported. aim: to compare the results of frozen thawed embryo transfers with and without gnrha analogue support primary end point: ir, pr, on going pr secondary end point: hch, e2 and progesterone levels 14 days after thawing


Eligibility criteria:
inclusion criteria: * 20 - 45 year old women comig to frozen thawed embryo transfer exclusion criteria: * the age of the woman over 42 years during the initial icf/icsi- treatment from which the embryos derive * abnormal uterus * known abnormality of karyotype of the woman or her partner * severe male factor as an exclusive reason for subfertility * allegy for triptorelin acetate
personalised health recommendations to the general population through an integrated ai guided

Conditions: Gastric Cancer; Cancer Prevention; Helicobacter Pylori Infection; Artificial Intelligence

Summary: this clinical study aims to be used to implement and validate the aida tool in two phases: * phase 1: risk stratification and personalised recommendations \& model development * phase 2: mechanistic model (bioresource) development \& testing

the aida objective (project) is to develop and validate a multidisciplinary ai-powered assistant that helps clinicians diagnose precancerous inflammation, suggests personalised therapeutic strategies for medical treatment and follow-up, and makes personalised recommendations for monitoring patient health status, thus contributing to gastric cancer prevention. this prospective clinical study aims to implement and validate such tool.

Eligibility criteria:
inclusion criteria: * subjects ≥ 18 years old with a diagnosis of gim or previous or current h. pylori infection, to whom a gastroscopy is indicated within clinical care * availability of a signed informed consent form to participate in the study exclusion criteria: * patients to whom an endoscopy is performed for the follow-up of another illness such as oesophageal varices and/or for therapy such as endoscopic dilation, feeding tube placement or endoscopic resection * subjects with a clinical diagnosis of gastric diseases other than gim or gc * patients who have received antimicrobials during the four weeks prior to the endoscopy * patients who have received proton pump inhibitors and/or bismuth-based treatments at least two weeks prior to the endoscopy * subjects for whom clinical data are not available: h. pylori status, eradication treatment, sex, age, tobacco smoking, and first-degree family history of gastric cancer * subjects who lack the mental capacity to understand the nature and requirements of the study and who lack the ability to give informed consent
to demonstrate the effect of food on the bioavailability of glipizide

Conditions: Type 2 Diabetes

Summary: to demonstrate the effect of food on the bioavailability of glipizide.


Eligibility criteria:
inclusion criteria: * no clinically significant abnormal finding on physical exam, medical history, or clinical laboratory results on screening. exclusion criteria: * positive test results for hiv or hepatitis b or c. * treatment for drug or alcohol dependence.
impact of polyphenols on endothelial function in obstructive sleep apnea

Conditions: Obstructive Sleep Apnea

Summary: severe obstructive sleep apnea (osa) is associated with increased cardiovascular morbidity and mortality. endothelial dysfunction, an early marker of vascular disease has been demonstrated in osa. regular treatment of osa by continuous positive airway pressure (cpap) improves endothelial function and is associated with a reduction in cardiovascular risk. approximately 40% of patients with osa are intolerant or insufficiently adherent to cpap. alternative treatments or adjuvants to the cpap are needed. the polyphenols have demonstrated their effectiveness in improving endothelial function in patients with cv disease. no randomized controlled studies have evaluated the impact of ppr on the endothelial dysfunction associated with osahs.

the endpoint is the change to one month of polyphenols treatment of the endothelial function measured by the index of hyperemic reactivity. the secondary endpoints are changes at one month of supplementation with polyphenols of ambulatory blood pressure measurement in 24 hours (mapa), micro-circulatory responsiveness, the speed of the pulse wave and biological measurements (lipid profile, blood glucose, fasting insulin, leptin, adiponectin, hs-crp, 8-isoprostane levels and cellular origin of microparticles).

Eligibility criteria:
inclusion criteria:• * apnea hypopnea index \> 30 * accepting polyphenols supplementation * signed informed consent exclusion criteria: * epworth sleepiness scale \> 16/24 * severe cardiac and/or respiratory disease * bmi\>35 kg/m2 * anemia

Keywords: sleep apnea polyphenols endothelial function
effect of insulin resistance on the safety and efficacy of pegylated interferon and ribavirin treatment in hcv (study p05562)

Conditions: Hepatitis C, Chronic; Hepatitis C Virus

Summary: naïve patients with chronic hepatitis c (chc) of any genotype will be treated with a standard treatment regimen (pegylated interferon and ribavirin) according to routine clinical practice in russia. the objective of this study is to examine the influence of insulin resistance on the safety and efficacy of treatment with pegylated interferon and ribavirin and to determine the prevalence of insulin resistance in different populations of chc patients.

consecutive patient sampling

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of chc according to local regulations * naïve pegylated interferon (peg-ifn) chc patient * no contraindications for peg-ifn chc therapy * negative urine pregnancy test result (for females of childbearing potential) documented within the 24-hour period prior to the first dose of study drugs. additionally, all female patients of childbearing potential and all males with female partners of childbearing potential must use two forms of effective contraception (combined) during treatment and 6 months after treatment end * willingness to give written informed consent and willingness to participate in and comply with the study requirements. exclusion criteria: * peg-ifn treatment in history * contraindications for peg-ifn chc therapy * females who are pregnant or breast-feeding * male partners of females who are pregnant * potentially unreliable participants, and those judged by the investigator to be unsuitable for the study.
treatment of atraumatic bone marrow edema with denosumab and teriparatide vs placebo

Conditions: Bone Marrow Oedema Syndrome; High Turnover Bone Disease; Quality of Life

Summary: the etiology of bone marrow edema (bme) is still uncertain. several studies report therapeutic success with antiresorptive drugs. this study investigates antiresorptive and osteoanabolic drugs versus placebo in bme

patients are assigned to receive either denosumab 60mg sc (once) or placebo or daily teriparatide sc for three months or placebo. mri examinations at baseline and after three months will be performed. serum bone turnover markers will be evaluated as well as qol questionnaires.

Eligibility criteria:
inclusion criteria: * mri diagnosed bone marrow edema exclusion criteria: * any prior antiresorptive or osteoanabolic treatment * any prior therapy with strontium ranelate * hyper-/hypocalcemia * malignancies * pregnancy * and contraindication against denosumab or teriparatide

Keywords: bone marrow edema, denosumab, pth 1-84
the safety and efficacy of cilostazol in ischemic stroke patients with peripheral arterial disease (spad study)

Conditions: Ischemic Stroke

Summary: the purpose of this study is to investigate the safety and efficacy of cilostazol in slowing down the progression of peripheral arterial disease (pad) in ischemic stroke patients with pad in taiwan.

one thousand patients will be randomized to take cilostazol (500 patients) or placebo (500 patients) in parallel groups. patients will be screened and evaluated on visits 1 to assess their eligibility prior to randomization. the treatment period (visit 1-6) will last 12 months and the patient will receive initial and follow-up evaluation (section 4.5) including history and physical examinations, and baseline and end of treatment abi and carotid imt assessments. vascular events and death as well as adverse events including bleeding complications will also be recorded at intervals as detailed in section 4.5.

Eligibility criteria:
inclusion criteria: * male or female patients, age ≧50 years; for female patients, postmenopausal (defined as at least 2 years without menses) has to be confirmed. * ischemic stroke or transient ischemic attack patients who have been taking aspirin 100 mg, qd * neurologically and clinically stable at inclusion * pad (i.e. ankle-brachial index or abi \<1.0) exclusion criteria: * patients unable to give informed consent * patients with history of any type of hemorrhagic stroke (intracerebral hemorrhage,subarachnoid hemorrhage, or others) * modified rankin scale \>4 * patients with history of dementia requiring institutional care * known brain tumor * known anemia (defined as hemoglobin \<10.0 g/dl) * known thrombocytopenia (defined as platelet count below 100,000/cm3) * ast or alt \> 3 x upper normal limit * calculated creatinine clearance \< 30 ml/min according to the copckroft formula) * known hemostasis or coagulation disorder * congestive heart failure, defined as a previous definitive diagnosis, or present symptoms of at least category ii of the nyha classification system for chf * revascularization of the lower limb arteries including bypass surgery, endovascular procedures * symptomatic pad requiring treatment with cilostazol * known stenosis of the upper limb arteries that may affect the documentation of abi * patients with known hypersensitivity to cilostazol
metabolic effects of non-nutritive sweeteners

Conditions: Obesity

Summary: the purpose of this research study is to examine whether sugar-replacement sweeteners that are currently on the market (ex. sucralose, which is in splenda) change how well the body works to control blood sugar.

the investigators of this study have recently found that sucralose, the most commonly used non-nutritive sweetener (nns), affects the glycemic response to an oral glucose tolerance test (ogtt) and potentiates glucose-stimulated insulin secretion in obese people who are not regular consumers of nns. however, studies conducted in healthy lean adults, none of which control for previous use of nns, show that sucralose does not affect glycemic or hormonal responses to the ingestion of glucose or other carbohydrates. therefore, we do not know a) whether sucralose effects are limited to obese subjects, or are generalizable to lean people when controlling for prior history of nns consumption, and b) mechanism(s) responsible for the acute effect of sucralose on glucose metabolism as we measured in obese subjects. the aim of this study is to determine the effects of an acute intake of sucralose on the metabolic response to an oral glucose tolerance test in lean and obese people.

Eligibility criteria:
inclusion criteria: * bmi ≥ 30 kg/m2 or bmi ≥ 18 kg/m2 and bmi\<25 kg/m2 * "insulin sensitive": based on the homeostasis model assessment of insulin resistance (homa-ir) \<3 exclusion criteria: * bmi ≥ 25 kg/m2 and bmi\<30 kg/m2 * homa-ir\>3 * current smoker or quit smoking less than 6 months ago * pregnancy or breastfeeding * subjects who have malabsorptive syndromes, phenylketonuria, inflammatory intestinal disease, liver or kidney diseases, diabetes * subjects who are taking any medication that might affect metabolism * anemia * regular use of non-nutritive sweeteners

Keywords: sucralose
hsp-glomerulonephritis trial: mp vs cya

Conditions: Purpura, Schoenlein-Henoch

Summary: no curative treatment of severe hsp nephritis is known. apart from corticosteroids, immunosuppressive drugs, such as azathioprine and cyclophosphamide, have been used to treat severe hsp nephritis.limited patient series treated with these drugs have been described, but there are no reports of controlled trials. cyclosporine a have been used to treat corticosteroid-resistant or corticosteroid-dependent nephrosis. (11) cyclosporine a has also been used to treat hsp nephritis, but as far as we know, there are no publications reporting such trials. the aim of the study is to compare mp pulses and cyclosporine a for their efficacy in the treatment of hsp nephritis. the efficacy of the two treatments will be assessed on the basis of the duration of nephrosis/nephritis, the maintenance of renal function and the renal biopsy findings.

using a prospective, randomised, open-labelled design, mp pulse treatment and cyclosporine a treatment will be compared for their efficacy in the treatment of severe hsp glomerulonephritis. the trial will be a national multi-centre trial that involves all finnish university hospitals, a few finnish central hospitals. the hsp patients with crescent hsp glomerulonephritis (iskdc class iii or iv) diagnosed by renal biopsy or with a renal biopsy finding of iskdc class ii + a distinct nephrotic syndrome will be included. most of the patients will be recruited from a series collected by the same authors to study the prevention of hsp nephritis (see effect of prednisone treatment on the symptoms of hsp disease and the development of glomerulonephritis). the patients will be randomised to receive either mp pulses i.v. or cyclosporine a p.o. the mp pulses will consist of three doses of methylprednisolone 30 mg/kg i.v. given over a period of one week in hospital. on the intermediate days and for a month after the mp pulses, the patients will be given prednisone 30 mg/m2/day p.o., after which the prednisone medication will be gradually tapered over 3 months. the patients randomised into the cyclosporine a group will receive an initial dose of 5 mg/kg/day, after which the dosage will be titrated to an optimal therapeutic level by monitoring the b-cya concentration. the cyclosporine a treatment will be continued for 12 months.

Eligibility criteria:
inclusion criteria: * on the basis of a renal biopsy, the patient has been diagnosed for crescentic hsp glomerulonephritis of iskdc grade iii or iv or hsp glomerulonephritis of iskdc grade ii + a definite nephrotic syndrome (proteinuria \> 40 mg/m2/h). exclusion criteria: * the child is on regular medication known to interact with cyclosporine. such medication includes cisapride, phenytoin, phenobarbital, carbamazepine, digoxin and anti-inflammatory pain medication.

Keywords: proteinuria nephritis nephrotic syndrome glomerulonephritis
storytelling to prevent obesity and encourage responsive feeding practices in young children

Conditions: Obesity, Childhood

Summary: the goal of this qualitative trial study is to assess the usefulness and acceptability of the intervention in diverse clinical and community settings. the main questions it aims to answer are: * how many parents were approached and consented to participate? * how many parents viewed the videos via link versus viewed the video with a discussion in group sessions? * how did parents feel about the process of being recruited and interventions that they participated in? * how did the providers feel about the intervention recruitment and delivery? * how did the facilitators feel about their delivery of the material? participants will complete a survey and an interview after completing second part of the intervention. researchers will compare handout, online-only video, and group class interventions to see if an intervention delivery is useful and accepted by parents or providers.

this is a pilot randomized trial to assess feasibility and acceptability of story. the study will recruit 30 parents. parents will complete a questionnaire and dyad's heights and weights will be measured. families will be randomized to the control group or 1 of 2 intervention delivery approaches (ia). parents will be given a handout (controls), links to the videos to watch independently (ia 1), or information on how they will be contacted to schedule their intervention sessions (ias 2). after 2 video/sessions, all parents will complete a written survey assessing their experience with the intervention and any change same at home; the written survey will reassess baseline measures. intervention parents will also complete a semi-structured interview to assess the family's experience with the story trial. sub aim 2a: feasibility: number of parents approached, number of parents consented sub aim 2b: adherence: number of parents who complete videos or sessions sub aim 2c: acceptability to parents and providers

Eligibility criteria:
inclusion criteria: * parent of 2-4 year old child * is at least 18 years old * participant can read and write english * the participant's child has no medical conditions that affect development, feeding, or growth exclusion criteria: * participant is not a parent of a 2-4 year old child * parent is less than 18 years old * parent can not read and write english * participant's child has a medical condition that affects development, feeding, or growth * family/household member participating in study

Keywords: obesity young children feeding practices obesity prevention obesity intervention child feeding questionnaire satiety responsiveness food responsiveness family meal frequency questionnaire structure of family meals
hairy cell leukemia: harnessing the full power of extracellular vesicles to improve patient care management

Conditions: Hairy Cell Leukemia (HCL)

Summary: check whether patients with hairy cell leukemia (hcl) of different status (at diagnosis, in complete remission \> 2 years or relapsed requiring therapy) have a 'signature' of altered immunity based on extracellular vesicles (ev)

extracellular vesicles are small particles detected within plasma and recognized as mediators of intercellular communication thanks to their cargo of proteins, lipids, and nucleic acids. however, the composition of vesicles from hairy cell leukemia patients, which may hold the key to unraveling their involvement and function within tumor microenvironment, is totally unknown. the aim of this study is to characterize these extracellular vesicles in order to identify biology-related and disease-specific biomarkers.

Eligibility criteria:
inclusion criteria for patients: * who2022-defined diagnosis of hairy cell leukemia. * age ≥18 years. * signed informed consent. inclusion criteria for healthy donors: * age ≥18 years. * volunteers in general good health, free from any disease or serious illness. * signed informed consent. exclusion criteria - none